Serotonergic	serotonergic	O	O	OTHERS	I
antidepressants	antidepressants	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
urinary	urinary	O	DISEASE	OTHERS	I
incontinence	incontinence	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Many	many	O	O	O	O
new	new	O	O	O	O
serotonergic	serotonergic	O	O	OTHERS	I
antidepressants	antidepressants	CHEMICALS	O	OTHERS	I
have	have	O	O	O	O
been	been	O	O	O	O
introduced	introduced	O	O	O	O
over	over	O	O	O	O
the	the	O	O	O	O
past	past	O	O	O	O
decade	decade	O	O	O	O
.	.	O	O	O	O

Although	although	O	O	O	O
urinary	urinary	O	DISEASE	OTHERS	I
incontinence	incontinence	O	DISEASE	OTHERS	I
is	is	O	O	O	O
listed	listed	O	O	O	O
as	as	O	O	O	O
one	one	O	O	O	O
side	side	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
drugs	drugs	O	O	O	O
in	in	O	O	O	O
their	their	O	O	O	O
package	package	O	O	O	O
inserts	inserts	O	O	O	O
there	there	O	O	O	O
is	is	O	O	O	O
only	only	O	O	O	O
one	one	O	O	O	O
report	report	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
literature	literature	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
concerns	concerns	O	O	O	O
2	2	O	O	O	O
male	male	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
experienced	experienced	O	O	O	O
incontinence	incontinence	O	DISEASE	OTHERS	I
while	while	O	O	O	O
taking	taking	O	O	O	O
venlafaxine	venlafaxine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
paper	paper	O	O	O	O
the	the	O	O	O	O
authors	authors	O	O	O	O
describe	describe	O	O	O	O
2	2	O	O	O	O
female	female	O	O	O	O
patients	patients	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
incontinence	incontinence	O	DISEASE	OTHERS	I
secondary	secondary	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
selective	selective	O	O	O	O
serotonin	serotonin	CHEMICALS	O	OTHERS	I
reuptake	reuptake	O	O	OTHERS	I
inhibitors	inhibitors	O	O	OTHERS	I
paroxetine	paroxetine	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
sertraline	sertraline	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
a	a	O	O	O	O
third	third	O	O	O	O
who	who	O	O	O	O
developed	developed	O	O	O	O
this	this	O	O	O	O
side	side	O	O	O	O
effect	effect	O	O	O	O
on	on	O	O	O	O
venlafaxine	venlafaxine	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
2	2	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
3	3	O	O	O	O
cases	cases	O	O	O	O
the	the	O	O	O	O
patients	patients	O	O	O	O
were	were	O	O	O	O
also	also	O	O	O	O
taking	taking	O	O	O	O
lithium	lithium	CHEMICALS	O	OTHERS	I
carbonate	carbonate	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
beta-blockers	beta-blockers	O	O	O	O
,	,	O	O	O	O
both	both	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
could	could	O	O	O	O
have	have	O	O	O	O
contributed	contributed	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
incontinence	incontinence	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Animal	animal	O	O	O	O
studies	studies	O	O	O	O
suggest	suggest	O	O	O	O
that	that	O	O	O	O
incontinence	incontinence	O	DISEASE	OTHERS	I
secondary	secondary	O	O	O	O
to	to	O	O	O	O
serotonergic	serotonergic	O	O	OTHERS	I
antidepressants	antidepressants	CHEMICALS	O	OTHERS	I
could	could	O	O	O	O
be	be	O	O	O	O
mediated	mediated	O	O	O	O
by	by	O	O	O	O
the	the	O	O	O	O
5HT4	5ht4	O	O	O	O
receptors	receptors	O	O	O	O
found	found	O	O	O	O
on	on	O	O	O	O
the	the	O	O	O	O
bladder	bladder	O	O	O	O
.	.	O	O	O	O

Further	further	O	O	O	O
research	research	O	O	O	O
is	is	O	O	O	O
needed	needed	O	O	O	O
to	to	O	O	O	O
delineate	delineate	O	O	O	O
the	the	O	O	O	O
frequency	frequency	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
troubling	troubling	O	O	O	O
side	side	O	O	O	O
effect	effect	O	O	O	O
and	and	O	O	O	O
how	how	O	O	O	O
best	best	O	O	O	O
to	to	O	O	O	O
treat	treat	O	O	O	O
it	it	O	O	O	O
.	.	O	O	O	O

